NETTUNIT - Italy-Tunisia Cross-border Environmental network

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

The study involves the development and validation of a questionnaire for risk perception to be administered to residents of areas declared to be at high risk of environmental crisis in the areas of Caltanissetta (Italy) and Tunis (Tunisia). The questionnaire will be administered twice, at baseline and after 1 month.

See also
	Status	Clinical Trial	Phase
	Completed	`NCT00588211` - Measurement of Cancer-Related Risk Perception in Smokers

NCT number	NCT05186896
Study type	Observational
Source	Istituto per la Ricerca e l'Innovazione Biomedica
Contact	Stefania La Grutta, MD
Phone	0916809194
Email	stefania.lagrutta@irib.cnr.it
Status	Recruiting
Phase
Start date	June 1, 2021
Completion date	March 3, 2023

NETTUNIT - Italy-Tunisia Cross-border Environmental network_2

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms